$MTVA
MetaVia Inc.

2024 Q2 Form 10-Q Financial Statement

#000155837024007479 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.010M $1.977M
YoY Change 39.39% 4.99%
% of Gross Profit
Research & Development $8.074M $4.904M
YoY Change 241.54% 669.86%
% of Gross Profit
Depreciation & Amortization $6.000K $4.000K
YoY Change 300.0%
% of Gross Profit
Operating Expenses $8.074M $4.904M
YoY Change 241.54% 669.86%
Operating Profit -$10.08M -$6.881M
YoY Change 164.95% 173.06%
Interest Expense $164.0K $237.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $31.00K $167.0K
YoY Change -98.99% -298.81%
Pretax Income -$10.05M -$6.714M
YoY Change 1269.62% 157.83%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.05M -$6.714M
YoY Change 1336.14% 157.83%
Net Earnings / Revenue
Basic Earnings Per Share -$1.85 -$1.32
Diluted Earnings Per Share -$1.85 -$1.32
COMMON SHARES
Basic Shares Outstanding 4.906M 4.906M
Diluted Shares Outstanding 5.429M 5.089M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.93M $15.99M
YoY Change -2.63% -48.11%
Cash & Equivalents $27.93M $16.00M
Short-Term Investments
Other Short-Term Assets $583.0K $508.0K
YoY Change 19.96% -24.18%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $28.52M $16.76M
YoY Change -2.25% -46.75%
LONG-TERM ASSETS
Property, Plant & Equipment $44.00K $47.00K
YoY Change 780.0% 840.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $21.00K $21.00K
YoY Change
Total Long-Term Assets $234.0K $254.0K
YoY Change 4580.0% 4980.0%
TOTAL ASSETS
Total Short-Term Assets $28.52M $16.76M
Total Long-Term Assets $234.0K $254.0K
Total Assets $28.75M $17.02M
YoY Change -1.47% -45.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.632M $2.079M
YoY Change 172.18% 85.79%
Accrued Expenses $2.601M $3.948M
YoY Change 27.44% 846.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.711M $6.825M
YoY Change 143.81% -37.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $98.00K $117.0K
YoY Change
Total Long-Term Liabilities $98.00K $117.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $9.711M $6.825M
Total Long-Term Liabilities $98.00K $117.0K
Total Liabilities $9.809M $6.942M
YoY Change 146.27% -36.78%
SHAREHOLDERS EQUITY
Retained Earnings -$125.0M -$115.0M
YoY Change 26.17% 16.87%
Common Stock $8.000K $5.000K
YoY Change -78.95% -81.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.94M $10.08M
YoY Change
Total Liabilities & Shareholders Equity $28.75M $17.02M
YoY Change -1.47% -45.95%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$10.05M -$6.714M
YoY Change 1336.14% 157.83%
Depreciation, Depletion And Amortization $6.000K $4.000K
YoY Change 300.0%
Cash From Operating Activities -$7.251M -$6.400M
YoY Change 254.57% 151.28%
INVESTING ACTIVITIES
Capital Expenditures $3.000K $5.000K
YoY Change 25.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.000K -$5.000K
YoY Change 25.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.20M 0.000
YoY Change -24100.0%
NET CHANGE
Cash From Operating Activities -7.251M -6.400M
Cash From Investing Activities -3.000K -5.000K
Cash From Financing Activities 19.20M 0.000
Net Change In Cash 11.95M -6.405M
YoY Change -662.16% 151.08%
FREE CASH FLOW
Cash From Operating Activities -$7.251M -$6.400M
Capital Expenditures $3.000K $5.000K
Free Cash Flow -$7.254M -$6.405M
YoY Change 254.72% 151.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001638287
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4906000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4906000
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.13
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.13
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.13
CY2023Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.13
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-37809
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
NeuroBo Pharmaceuticals, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2389984
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
545 Concord Avenue, Suite 210
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge,
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02138
CY2024Q1 dei City Area Code
CityAreaCode
857
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
702-9600
CY2024Q1 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
77000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
16764000
CY2024Q1 dei Trading Symbol
TradingSymbol
NRBO
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4906002
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15988000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22435000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
776000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
22512000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
186000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
202000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000
CY2024Q1 us-gaap Assets
Assets
17018000
CY2023Q4 us-gaap Assets
Assets
22781000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2079000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
821000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3948000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4414000
CY2024Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Current
SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
728000
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Current
SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
658000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
70000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
67000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6825000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5960000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
117000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
136000
CY2024Q1 us-gaap Liabilities
Liabilities
6942000
CY2023Q4 us-gaap Liabilities
Liabilities
6096000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4906000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4906000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
125050000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
124945000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114979000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108265000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
10076000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16685000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17018000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22781000
CY2024Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4904000
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
637000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1977000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1883000
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
6881000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
2520000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6881000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2520000
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
70000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
84000
CY2024Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
237000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
167000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-84000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6714000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2604000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6714000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6714000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2604000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2604000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5089408
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5059003
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21750000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1436000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-74000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2604000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
20508000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16685000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
105000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6714000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
10076000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6714000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2604000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
105000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
-74000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1000
CY2024Q1 us-gaap Depreciation
Depreciation
4000
CY2023Q1 us-gaap Depreciation
Depreciation
1000
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
70000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
84000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
699000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
502000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1258000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
411000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-467000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
137000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6442000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2547000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6447000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2551000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22435000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33364000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15988000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30813000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1436000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16000000.0
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115000000.0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6700000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6400000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">C.</b></span><b style="font-weight:bold;">Estimates and assumptions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in our consolidated financial statements relate to accrued expenses and the fair value of stock-based compensation and warrants. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
203914
CY2024Q1 nrbo Class Of Warrant Or Right Securities Called By Each Warrant Or Right Number Of Warrants Exchanged
ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged
8
CY2024Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0
CY2024Q1 nrbo Prepaid Clinical Costs
PrepaidClinicalCosts
195000
CY2023Q4 nrbo Prepaid Clinical Costs
PrepaidClinicalCosts
13000
CY2024Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
73000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
508000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
64000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
776000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
77000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
85000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
80000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
38000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
34000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46000
CY2024Q1 nrbo Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
3336000
CY2023Q4 nrbo Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
3822000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
210000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
118000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
337000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
308000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
65000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
166000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3948000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4414000
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
203914
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
104000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-74000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
416227
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4700
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
398.30
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4577
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
391.04
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y7M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4700
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
398.30
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4607
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
392.96
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M18D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.63
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
141361
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.55
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
523000
CY2023Q4 nrbo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber
5468
CY2023Q4 nrbo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue
4.02
CY2023Q4 nrbo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested Balance
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedBalance
20000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
53593
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.24
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
194954
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.02
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
797000
CY2024Q1 nrbo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber
5468
CY2024Q1 nrbo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue
4.02
CY2024Q1 nrbo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested Balance
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedBalance
22000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6714000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2604000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5089408
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5059003
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5089408
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5059003
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51

Files In Submission

Name View Source Status
0001558370-24-007479-index-headers.html Edgar Link pending
0001558370-24-007479-index.html Edgar Link pending
0001558370-24-007479.txt Edgar Link pending
0001558370-24-007479-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrbo-20240331.xsd Edgar Link pending
nrbo-20240331x10q.htm Edgar Link pending
nrbo-20240331x10q001.jpg Edgar Link pending
nrbo-20240331xex10d1.htm Edgar Link pending
nrbo-20240331xex31d1.htm Edgar Link pending
nrbo-20240331xex31d2.htm Edgar Link pending
nrbo-20240331xex32d1.htm Edgar Link pending
nrbo-20240331xex32d2.htm Edgar Link pending
nrbo-20240331xex3d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nrbo-20240331_cal.xml Edgar Link unprocessable
nrbo-20240331_def.xml Edgar Link unprocessable
nrbo-20240331_lab.xml Edgar Link unprocessable
nrbo-20240331_pre.xml Edgar Link unprocessable
nrbo-20240331x10q_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending